Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Leyden Labs
Leyden Labs

Leyden Labs

Series D

Leyden Labs develops intranasal therapies for influenza and respiratory virus protection.

HQ
Leiden, NL
Founded
2020
Overview
M & A
Compare
Fundraising
Employees
News

Leyden Labs develops mucosal and intranasal medicines aimed at broad protection against respiratory viruses.

Its work includes nasal spray approaches for influenza prevention and other respiratory threat protection.

Leyden Labs - M & A Snapshot

Open M & A
  • CoVBio

    Acquired by Leyden Labs • Undisclosed • Jan 9, 2025

Leyden Labs - Similar Companies

Nota Labs logo

Nota Labs

notalabs.com

Lydex logo

Lydex

CoVBio logo

CoVBio

covbiotech.com

Flugen logo

Flugen

Virvio logo

Virvio

Endolytix logo

Endolytix

Lyra Therapeutics logo

Lyra Therapeutics

Calder Biosciences logo

Calder Biosciences

Inhalon Biopharma logo

Inhalon Biopharma

inhalon.com

SaNOtize logo

SaNOtize

sanotize.com

Vivaldi Biosciences logo

Vivaldi Biosciences

MaskZero logo

MaskZero

maskzero.us

Lyndra logo

Lyndra

lyndra.com

Respira Labs logo

Respira Labs

Nikira Labs logo

Nikira Labs

Leyden Labs - Quick Facts

Who are Leyden Labs' competitors?

Companies similar to Leyden Labs include Nota Labs, Lydex, CoVBio and Flugen.

When was Leyden Labs founded?

Leyden Labs was founded in 2020.

Where is Leyden Labs' headquarters located?

Leyden Labs' headquarters is located in Leiden, NL.

When was Leyden Labs' last funding round?

Leyden Labs' most recent funding round was for $40M (USD) in June 2026.

How much has Leyden Labs raised to-date?

As of Jun 25, 2026, Leyden Labs has raised a total of $40M (USD).

Leyden Labs - Classification

Industry
  • Biotechnology